Tokyo, July 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058492) titled 'Assessment of patients' immune cells and efficacy of CAR-T cell therapy' on July 16.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Ehime University Graduate School of Medicine
Condition:
Condition - Hematological malignancies
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To elucidate the factors associated with treatment efficacy and safety of CAR-T cell therapy through the anaylses using patients' samples obtained before/after CAR-T cell therapy.
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - To adjust the dose and duration of therapeutic drugs for adverse events based on patients' immune cells after CAR-T cell therapy.
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients with hematological malignancies treated with CAR-T cell therapy.
Key exclusion criteria - Patients with hematological malignancies who are not treated with CAR-T cell therapy.
Target Size - 50
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 02 Month 25 Day
Date of IRB - 2025 Year 02 Month 25 Day
Anticipated trial start date - 2025 Year 02 Month 25 Day
Last follow-up date - 2033 Year 01 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066877
Disclaimer: Curated by HT Syndication.
